Bioinformatic Investigation of the Effects of Romidepsin and Tamoxifen Compounds in Inhibiting Histone Deacetylase Enzyme for Cancer Treatment
Keywords:
Histone deacetylase, Cancer, Romidepsin, TamoxifenAbstract
Cancer is a complex group of diseases, and the transformation of a normal cell into a cancerous one is a complicated, multi-step process resulting from abnormal gene expression and regulation. This study aims to conduct a bioinformatic investigation of the effects of romidepsin and tamoxifen compounds in inhibiting the human histone deacetylase (HDAC) enzyme. HDACs play a crucial role in gene expression regulation by remodeling chromatin structure. An imbalance in histone acetylation, caused by dysregulated HDAC expression and activity, is known to contribute to cancer progression in various malignancies. Therefore, this research seeks to target HDAC inhibition as a therapeutic strategy against cancer.
The studied compounds were downloaded from the PubChem database. The target enzyme was also obtained from the PDB database, optimized using Chimera and Discovery software, and subjected to molecular docking via the HDock server. Finally, the results were analyzed and evaluated using the two aforementioned software tools and the PDBsum Generate website.
The studied compounds were capable of occupying the enzymes' active sites, with binding energy levels of -144.17 kcal/mol for tamoxifen and -140.42 kcal/mol for romidepsin.
Given the efficacy of these compounds in the bioinformatic analysis, further investigations under in vitro and in vivo conditions are recommended to validate their therapeutic potential.
Downloads
References
[1] Uçar, T., E. Güney, and Z. Bal, Psychosocial Aspecets of Gynecologic Canser. Sakarya Tıp Dergisi,
2018. 8(4): p. 678-685.
[2] Sheehan, L., et al., Implementing community-based participatory research among African Americans with
serious and persistent mental illness: A qualitative study. Gateways: International Journal of Community
Research and Engagement, 2021. 14(1): p. 1-19.
[3] De-Rufino Rivas, P.M., et al., Evaluación del riesgo nutricional de los adolescentes escolarizados en
Cantabria. Nutrición Hospitalaria, 2014. 29(3): p. 652-657.
[4] Smolewski, P. and T. Robak, The discovery and development of romidepsin for the treatment of T-cell
lymphoma. Expert opinion on drug discovery, 2017. 12(8): p. 859-873.
[5] El Omari, N., et al., Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of
romidepsin. Biomedicine & Pharmacotherapy, 2023. 164: p. 114774.
[6] Ahmad, I., Tamoxifen a pioneering drug: An update on the therapeutic potential of tamoxifen
derivatives. European journal of medicinal chemistry, 2018. 143: p. 515-531.
[7] Jordan, V.C., Tamoxifen: a most unlikely pioneering medicine. Nature reviews Drug discovery, 2003.
2(3): p. 205-213.
[8] Dokmanovic, M., C. Clarke, and P.A. Marks, Histone deacetylase inhibitors: overview and perspectives.
Molecular cancer research, 2007. 5(10): p. 981-989.
[9] Gray, S.G. and T.J. Ekström, The human histone deacetylase family. Experimental cell research, 2001.
262(2): p. 75-83.
[10] Barneda-Zahonero, B. and M. Parra, Histone deacetylases and cancer. Molecular oncology, 2012. 6(6):
p. 579-589.
[11] Drakontaeidi, A. and E. Pontiki, A Review on Molecular Docking on HDAC Isoforms: Novel Tool for
Designing Selective Inhibitors. Current Medicinal Chemistry, 2023.
[12] Arthura, D.E., Z. Chellube, A.O. Arohb, E.I. Edache, B.O. Elegbe, and A.P. Patrick, Molecular Docking
Study of Some HDAC Inhibitors. Nigerian Journal of Pharmaceutical and Biomedical Research, 2023.
[13] Scafuri, B., P. Bontempo, L. Altucci, L. De Masi, and A. Facchiano, Molecular Docking Simulations on
Histone Deacetylases (HDAC)-1 and -2 to Investigate the Flavone Binding. Biomedicines, 2020.
